JP5501766B2 - 肝細胞癌における生存および転移を予測するためのマイクロｒｎａ発現サイン - Google Patents
肝細胞癌における生存および転移を予測するためのマイクロｒｎａ発現サイン Download PDFInfo
- Publication number
- JP5501766B2 JP5501766B2 JP2009535366A JP2009535366A JP5501766B2 JP 5501766 B2 JP5501766 B2 JP 5501766B2 JP 2009535366 A JP2009535366 A JP 2009535366A JP 2009535366 A JP2009535366 A JP 2009535366A JP 5501766 B2 JP5501766 B2 JP 5501766B2
- Authority
- JP
- Japan
- Prior art keywords
- mir
- hcc
- mirna
- seq
- gene product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010073071 hepatocellular carcinoma Diseases 0.000 title claims description 147
- 231100000844 hepatocellular carcinoma Toxicity 0.000 title claims description 137
- 230000004083 survival effect Effects 0.000 title claims description 33
- 206010027476 Metastases Diseases 0.000 title claims description 31
- 230000009401 metastasis Effects 0.000 title claims description 30
- 108700011259 MicroRNAs Proteins 0.000 title description 38
- 230000014509 gene expression Effects 0.000 title description 38
- 108091070501 miRNA Proteins 0.000 claims description 227
- 239000002679 microRNA Substances 0.000 claims description 169
- 108090000623 proteins and genes Proteins 0.000 claims description 111
- 239000000523 sample Substances 0.000 claims description 64
- 238000000034 method Methods 0.000 claims description 52
- 238000012360 testing method Methods 0.000 claims description 49
- 206010028980 Neoplasm Diseases 0.000 claims description 47
- 230000001105 regulatory effect Effects 0.000 claims description 28
- 108091090020 miR-207 stem-loop Proteins 0.000 claims description 23
- 108091063841 miR-219 stem-loop Proteins 0.000 claims description 23
- 108091055059 miR-30c stem-loop Proteins 0.000 claims description 23
- 108091055434 miR-124a stem-loop Proteins 0.000 claims description 20
- 108091082871 miR-124a-2 stem-loop Proteins 0.000 claims description 20
- 108091050112 miR-124a-4 stem-loop Proteins 0.000 claims description 20
- 108091054623 miR-124a-5 stem-loop Proteins 0.000 claims description 20
- 108091024680 miR-124a-6 stem-loop Proteins 0.000 claims description 20
- 238000009396 hybridization Methods 0.000 claims description 19
- 238000002493 microarray Methods 0.000 claims description 17
- 108091034117 Oligonucleotide Proteins 0.000 claims description 15
- 239000013068 control sample Substances 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 229940046166 oligodeoxynucleotide Drugs 0.000 claims description 12
- 230000000683 nonmetastatic effect Effects 0.000 claims description 11
- 230000008859 change Effects 0.000 claims description 10
- 239000003153 chemical reaction reagent Substances 0.000 claims description 10
- 238000002372 labelling Methods 0.000 claims description 7
- 230000002441 reversible effect Effects 0.000 claims description 7
- 238000001514 detection method Methods 0.000 claims description 5
- 230000002411 adverse Effects 0.000 claims description 3
- 108091026890 Coding region Proteins 0.000 claims 1
- 210000003462 vein Anatomy 0.000 claims 1
- 239000000047 product Substances 0.000 description 87
- 210000004027 cell Anatomy 0.000 description 50
- 238000004458 analytical method Methods 0.000 description 20
- 238000004393 prognosis Methods 0.000 description 20
- 201000011510 cancer Diseases 0.000 description 18
- 239000003795 chemical substances by application Substances 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 14
- 230000000295 complement effect Effects 0.000 description 12
- 230000000875 corresponding effect Effects 0.000 description 12
- 230000001394 metastastic effect Effects 0.000 description 10
- 206010061289 metastatic neoplasm Diseases 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 9
- 210000005228 liver tissue Anatomy 0.000 description 9
- 108020004707 nucleic acids Proteins 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- 150000007523 nucleic acids Chemical class 0.000 description 9
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 8
- 238000003491 array Methods 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 238000003745 diagnosis Methods 0.000 description 6
- 238000002271 resection Methods 0.000 description 6
- 238000010824 Kaplan-Meier survival analysis Methods 0.000 description 5
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 5
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 5
- 238000012790 confirmation Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000010837 poor prognosis Methods 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 238000007473 univariate analysis Methods 0.000 description 5
- 206010016654 Fibrosis Diseases 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000007882 cirrhosis Effects 0.000 description 4
- 208000019425 cirrhosis of liver Diseases 0.000 description 4
- 238000002790 cross-validation Methods 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 238000000491 multivariate analysis Methods 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000005907 cancer growth Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000010195 expression analysis Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000012549 training Methods 0.000 description 3
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 206010045168 Tumour embolism Diseases 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000002074 deregulated effect Effects 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000007417 hierarchical cluster analysis Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000006193 liquid solution Substances 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 108091027963 non-coding RNA Proteins 0.000 description 2
- 102000042567 non-coding RNA Human genes 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000002853 nucleic acid probe Substances 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 238000000611 regression analysis Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 231100000588 tumorigenic Toxicity 0.000 description 2
- 230000000381 tumorigenic effect Effects 0.000 description 2
- 210000001631 vena cava inferior Anatomy 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000047351 Exportin-5 Human genes 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000847058 Homo sapiens Exportin-5 Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 1
- 102000003661 Ribonuclease III Human genes 0.000 description 1
- 108010057163 Ribonuclease III Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 238000011256 aggressive treatment Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 238000003766 bioinformatics method Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000004640 cellular pathway Effects 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000001953 common bile duct Anatomy 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 238000011223 gene expression profiling Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 108091053410 let-7 family Proteins 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000001325 log-rank test Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 108091062762 miR-21 stem-loop Proteins 0.000 description 1
- 108091041631 miR-21-1 stem-loop Proteins 0.000 description 1
- 108091044442 miR-21-2 stem-loop Proteins 0.000 description 1
- 238000012775 microarray technology Methods 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002991 molded plastic Substances 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 238000003499 nucleic acid array Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000011470 radical surgery Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000012706 support-vector machine Methods 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85589506P | 2006-11-01 | 2006-11-01 | |
| US60/855,895 | 2006-11-01 | ||
| PCT/US2007/023660 WO2008054828A2 (en) | 2006-11-01 | 2007-11-01 | Microrna expression signature for predicting survival and metastases in hepatocellular carcinoma |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010508042A JP2010508042A (ja) | 2010-03-18 |
| JP2010508042A5 JP2010508042A5 (OSRAM) | 2012-03-01 |
| JP5501766B2 true JP5501766B2 (ja) | 2014-05-28 |
Family
ID=39344934
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009535366A Expired - Fee Related JP5501766B2 (ja) | 2006-11-01 | 2007-11-01 | 肝細胞癌における生存および転移を予測するためのマイクロｒｎａ発現サイン |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US8252538B2 (OSRAM) |
| EP (1) | EP2087135B8 (OSRAM) |
| JP (1) | JP5501766B2 (OSRAM) |
| AU (1) | AU2007314212B2 (OSRAM) |
| CA (1) | CA2667617A1 (OSRAM) |
| ES (1) | ES2425416T3 (OSRAM) |
| WO (1) | WO2008054828A2 (OSRAM) |
Families Citing this family (103)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2290070B1 (en) * | 2004-05-28 | 2015-03-25 | Asuragen, Inc. | Methods and compositions involving microRNA |
| JP5489459B2 (ja) | 2005-08-01 | 2014-05-14 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション | 乳癌の診断、予後及び治療のためのマイクロｒｎａに基づいた方法及び組成物 |
| CN101296702B (zh) * | 2005-09-12 | 2012-11-28 | 俄亥俄州立大学研究基金会 | 用于诊断或治疗bcl2相关癌症的组合物和方法 |
| CN101312740A (zh) * | 2005-10-05 | 2008-11-26 | 俄亥俄州立大学研究基金会 | Wwox基因、包含该基因的载体和在癌症治疗中的用途 |
| WO2007081680A2 (en) | 2006-01-05 | 2007-07-19 | The Ohio State University Research Foundation | Microrna expression abnormalities in pancreatic endocrine and acinar tumors |
| ES2553442T3 (es) | 2006-01-05 | 2015-12-09 | The Ohio State University Research Foundation | Procedimientos basados en los microARN para el diagnóstico, pronóstico y tratamiento del cáncer de pulmón |
| ES2536423T3 (es) | 2006-01-05 | 2015-05-25 | The Ohio State University Research Foundation | Métodos basados en microARN para el diagnóstico de cáncer de próstata |
| EP2369012A1 (en) | 2006-03-20 | 2011-09-28 | The Ohio State University Research Foundation | Micro-RNA fingerprints during human megakaryocytopoiesis |
| ES2442890T3 (es) | 2006-07-13 | 2014-02-14 | The Ohio State University Research Foundation | Métodos y composiciones basados en micro-ARN para el diagnóstico y el tratamiento de enfermedades relacionadas con el colon |
| ES2374446T3 (es) | 2006-09-19 | 2012-02-16 | The Ohio State University Research Foundation | Expresión de tcl1 en la leucemia linfocítica crónica (llc) regulada por mir-29 y mir-181. |
| EP2087135B8 (en) | 2006-11-01 | 2013-07-24 | The Ohio State University Research Foundation | Microrna expression signature for predicting survival and metastases in hepatocellular carcinoma |
| CN105256004A (zh) | 2007-01-31 | 2016-01-20 | 俄亥俄州立大学研究基金会 | 用于急性髓细胞白血病(aml)的诊断、预后和治疗的基于微rna的方法和组合物 |
| EP2142659A4 (en) * | 2007-04-30 | 2010-06-09 | Univ Ohio State Res Found | METHOD FOR THE DISTINCTION OF PANCREATIC CANCER OF NORMAL IMMERSION SPECTRUM FUNCTIONS AND CHRONIC IMMERSION IMAGING IGNITION |
| ES2537349T3 (es) * | 2007-06-08 | 2015-06-05 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Métodos para determinar un subtipo de carcinoma hepatocelular |
| CN101918424A (zh) | 2007-06-15 | 2010-12-15 | 俄亥俄州立大学研究基金会 | 用于靶向由Drosha介导的微小RNA加工的致癌ALL-1融合蛋白 |
| JP2010535782A (ja) * | 2007-07-31 | 2010-11-25 | ズィ、オハイオウ、ステイト、ユーニヴァーサティ、リサーチ、ファウンデイシャン | Ｄｎｍｔ３ａ及びｄｎｍｔ３ｂを標的にすることによるメチル化を元に戻す方法 |
| ES2562077T3 (es) | 2007-08-03 | 2016-03-02 | The Ohio State University Research Foundation | Regiones ultraconservadas que codifican ARNnc |
| EP2183593B1 (en) * | 2007-08-22 | 2016-01-13 | The Ohio State University Research Foundation | Methods and compositions for inducing deregulation of epha7 and erk phosphorylation in human acute leukemias |
| AU2008310704B2 (en) * | 2007-10-11 | 2014-03-20 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Methods and compositions for the diagnosis and treatment of esphageal adenocarcinomas |
| EP2201112A4 (en) | 2007-10-26 | 2011-02-02 | Univ Ohio State Res Found | METHOD FOR IDENTIFYING FHIT INTERACTION AND USE |
| WO2009058907A2 (en) | 2007-10-29 | 2009-05-07 | Isis Pharmaceuticals, Inc. | Targeting micrornas for the treatment of liver cancer |
| WO2009070653A1 (en) * | 2007-11-30 | 2009-06-04 | The Ohio State University Research Foundation | Microrna expression profiling and targeting in peripheral blood in lung cancer |
| ES2600165T3 (es) * | 2008-02-28 | 2017-02-07 | The Ohio State University Research Foundation | Antagonistas de miR-32 para aumentar la respuesta del cáncer de próstata a la apoptosis |
| JP2011517932A (ja) * | 2008-02-28 | 2011-06-23 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション | ヒト慢性リンパ球性白血病（ｃｃｌ）と関連するマイクロｒｎａシグネチャーおよびその使用 |
| US9125923B2 (en) | 2008-06-11 | 2015-09-08 | The Ohio State University | Use of MiR-26 family as a predictive marker for hepatocellular carcinoma and responsiveness to therapy |
| CN101368213A (zh) * | 2008-10-13 | 2009-02-18 | 南京大学 | 血清微小核糖核酸试剂盒及其在乙肝早期诊断中的应用 |
| EP2196543A1 (en) * | 2008-12-15 | 2010-06-16 | Koninklijke Philips Electronics N.V. | Compositions and methods for micro-rna expression profiling of hepatocellular cancer |
| ITMI20091538A1 (it) * | 2009-09-07 | 2011-03-08 | Istituto Naz Di Genetica Mole Colare Ingm | Profili di espressione di micro-rna nel sangue periferico di pazienti affetti da epatocarcinoma o cirrosi epatica e loro usi |
| US8916533B2 (en) | 2009-11-23 | 2014-12-23 | The Ohio State University | Materials and methods useful for affecting tumor cell growth, migration and invasion |
| US20130065946A1 (en) | 2010-03-26 | 2013-03-14 | The Ohio State University | Materials and Methods Related to Modulation of Mismatch Repair and Genomic Stability by miR-155 |
| CN102399852A (zh) * | 2010-09-08 | 2012-04-04 | 上海市公共卫生临床中心 | 用于预测干扰素治疗慢性乙型肝炎疗效的血浆miRNA谱及检测试剂盒 |
| CN102021169A (zh) * | 2010-10-14 | 2011-04-20 | 南京大学 | 一种血清/血浆miRNA组合物及其应用 |
| ES2606146T3 (es) | 2010-11-12 | 2017-03-22 | The Ohio State University Research Foundation | Métodos relacionados con microARN-21 y reparación de desapareamiento en cáncer colorrectal |
| BR112013011942A2 (pt) | 2010-11-15 | 2016-11-01 | Univ Michigan | formulação, forma de dosagem de droga para administração transmucosa oral, sistema transmucoso de fornecimento de droga, método de tratamento e profilaxia de uma doença ou distúrbio, método de tratamento, formulação, método para tratamento ou prevenção de carcinoma de célula escamosa de cabeça e pescoço (hnscc), método para quimioprevenção de um câncer oral ou condição pré-cancerosa, método para aumentar a concentração de uma composição de retinida, método de tratamento e profilaxia de uma doença ou condição, método de ratamento de um sujeito apresentando uma condição médica sintomática, método de tratamento de um câncer oral ou condição pré-cancerosa num paciente, método para fazer um sistema de fornecimento de droga bucal, método para aumentar a liberação e permeação de uma composição de retinida. |
| US9150926B2 (en) | 2010-12-06 | 2015-10-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Diagnosis and treatment of adrenocortical tumors using human microRNA-483 |
| EP2683387A4 (en) | 2011-03-07 | 2014-09-03 | Univ Ohio State | MUTATOR ACTIVITY INDUCED BY MICRORNA-155 (miR-155) LINKS INFLAMMATION AND CANCER |
| WO2012151212A1 (en) * | 2011-05-01 | 2012-11-08 | University Of Rochester | Multifocal hepatocellular carcinoma microrna expression patterns and uses thereof |
| CN102776185B (zh) * | 2011-05-06 | 2013-07-10 | 复旦大学附属中山医院 | 由血浆microRNA组合成的肝癌诊断标志物及一种诊断肝癌的新方法 |
| JP5753905B2 (ja) * | 2011-05-06 | 2015-07-22 | チョンシャン ホスピタル フダン ユニバーシティ | 血漿ｍｉｃｒｏＲＮＡの組合せからなる肝細胞がん診断マーカーを含む、肝細胞がんの診断キット |
| CN104364390B (zh) | 2011-10-14 | 2016-08-24 | 俄亥俄州立大学 | 与卵巢癌相关的方法和材料 |
| NO3051026T3 (OSRAM) | 2011-10-21 | 2018-07-28 | ||
| CA2859430A1 (en) | 2011-12-13 | 2013-06-20 | Ohio State Innovation Foundation | Methods and compositions related to mir-21 and mir-29a, exosome inhibition, and cancer metastasis |
| JP2015503356A (ja) | 2012-01-06 | 2015-02-02 | バイオミクス, インコーポレイテッドViomics, Inc. | 末梢血中で、がんによって変化したｒｎａを検出するシステムおよび方法 |
| CA2866052A1 (en) | 2012-01-20 | 2013-07-25 | The Ohio State University | Breast cancer biomarker signatures for invasiveness and prognosis |
| WO2013148147A1 (en) | 2012-03-26 | 2013-10-03 | The U.S.A., As Represented By The Secretary Dept. Of Health And Human Services | Dna methylation analysis for the diagnosis, prognosis and treatment of adrenal neoplasms |
| US8846316B2 (en) * | 2012-04-30 | 2014-09-30 | Industrial Technology Research Institute | Biomarker for human liver cancer |
| US20150307542A1 (en) | 2012-10-03 | 2015-10-29 | Moderna Therapeutics, Inc. | Modified nucleic acid molecules and uses thereof |
| DK2922554T3 (en) | 2012-11-26 | 2022-05-23 | Modernatx Inc | Terminalt modificeret rna |
| JP2016504050A (ja) | 2013-01-17 | 2016-02-12 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 細胞表現型の改変のためのシグナルセンサーポリヌクレオチド |
| CN103898219A (zh) * | 2014-04-01 | 2014-07-02 | 镇江市第三人民医院 | 用于检测原发性胆汁性肝硬化的血清miRNA标志物及标志物组合及应用 |
| CN104293914A (zh) * | 2014-09-05 | 2015-01-21 | 镇江市第三人民医院 | 用于检测原发性肝细胞癌的血清miRNA标志物组合及应用 |
| EP3041948B1 (en) | 2014-11-10 | 2019-01-09 | Modernatx, Inc. | Alternative nucleic acid molecules containing reduced uracil content and uses thereof |
| US11640849B2 (en) * | 2015-09-10 | 2023-05-02 | Crown Bioscience, Inc. (Taicang) | Methods for histological diagnosis and treatment of diseases |
| WO2017127750A1 (en) | 2016-01-22 | 2017-07-27 | Modernatx, Inc. | Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof |
| WO2017180587A2 (en) | 2016-04-11 | 2017-10-19 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| EP3458083B1 (en) | 2016-05-18 | 2022-11-02 | ModernaTX, Inc. | Polynucleotides encoding interleukin-12 (il12) and uses thereof |
| CA3027201A1 (en) | 2016-06-14 | 2017-12-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| US11564997B2 (en) | 2016-06-29 | 2023-01-31 | Crispr Therapeutics Ag | Materials and methods for treatment of friedreich ataxia and other related disorders |
| WO2018002812A1 (en) | 2016-06-29 | 2018-01-04 | Crispr Therapeutics Ag | Materials and methods for treatment of myotonic dystrophy type 1 (dm1) and other related disorders |
| EP3478313B1 (en) | 2016-06-29 | 2022-05-04 | CRISPR Therapeutics AG | Materials and methods for treatment of amyotrophic lateral sclerosis (als) and other related disorders |
| CA3029132A1 (en) | 2016-07-06 | 2018-01-11 | Crispr Therapeutics Ag | Materials and methods for treatment of pain related disorders |
| US11459587B2 (en) | 2016-07-06 | 2022-10-04 | Vertex Pharmaceuticals Incorporated | Materials and methods for treatment of pain related disorders |
| KR20190086681A (ko) | 2016-10-26 | 2019-07-23 | 모더나티엑스, 인크. | 면역 반응을 향상시키기 위한 메신저 리보핵산 및 그의 사용 방법 |
| US11583504B2 (en) | 2016-11-08 | 2023-02-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| EA201991804A1 (ru) | 2017-02-01 | 2020-02-07 | МОДЕРНАТиЭкс, ИНК. | ИММУНОМОДУЛИРУЮЩИЕ ТЕРАПЕВТИЧЕСКИЕ КОМПОЗИЦИИ мРНК, КОДИРУЮЩЕЙ ПЕПТИДЫ С АКТИВИРУЮЩЕЙ ОНКОГЕННОЙ МУТАЦИЕЙ |
| EP3585807A1 (en) | 2017-02-22 | 2020-01-01 | CRISPR Therapeutics AG | Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders |
| US11407997B2 (en) | 2017-02-22 | 2022-08-09 | Crispr Therapeutics Ag | Materials and methods for treatment of primary hyperoxaluria type 1 (PH1) and other alanine-glyoxylate aminotransferase (AGXT) gene related conditions or disorders |
| EP3585898A1 (en) | 2017-02-22 | 2020-01-01 | CRISPR Therapeutics AG | Materials and methods for treatment of spinocerebellar ataxia type 1 (sca1) and other spinocerebellar ataxia type 1 protein (atxn1) gene related conditions or disorders |
| US20200216857A1 (en) | 2017-02-22 | 2020-07-09 | Crispr Therapeutics Ag | Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders |
| CN110662838B (zh) | 2017-02-22 | 2024-05-28 | 克里斯珀医疗股份公司 | 用于基因编辑的组合物和方法 |
| US20200131498A1 (en) | 2017-06-14 | 2020-04-30 | Modernatx, Inc. | Polynucleotides encoding methylmalonyl-coa mutase |
| CN111315359A (zh) | 2017-08-31 | 2020-06-19 | 摩登纳特斯有限公司 | 制备脂质纳米颗粒的方法 |
| MA50877A (fr) | 2017-11-21 | 2020-09-30 | Bayer Healthcare Llc | Matériaux et méthodes pour le traitement de la rétinite pigmentaire autosomique dominante |
| CA3084633A1 (en) | 2017-12-21 | 2019-06-27 | Crispr Therapeutics Ag | Materials and methods for treatment of usher syndrome type 2a and/or non-syndromic autosomal recessive retinitis pigmentosa (arrp) |
| AU2018393050A1 (en) | 2017-12-21 | 2020-06-18 | Bayer Healthcare Llc | Materials and methods for treatment of Usher Syndrome Type 2A |
| EP3514756A1 (en) * | 2018-01-18 | 2019-07-24 | Koninklijke Philips N.V. | Medical analysis method for predicting metastases in a test tissue sample |
| JP2021512090A (ja) | 2018-01-30 | 2021-05-13 | モデルナティーエックス， インコーポレイテッド | 免疫細胞に薬剤を送達するための組成物及び方法 |
| US20210163928A1 (en) | 2018-04-11 | 2021-06-03 | Modernatx, Inc. | Messenger rna comprising functional rna elements |
| WO2019241315A1 (en) | 2018-06-12 | 2019-12-19 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| WO2020061457A1 (en) | 2018-09-20 | 2020-03-26 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| US20210386788A1 (en) | 2018-10-24 | 2021-12-16 | Obsidian Therapeutics, Inc. | Er tunable protein regulation |
| KR102256747B1 (ko) * | 2018-10-30 | 2021-05-25 | 가톨릭대학교 산학협력단 | 엑소좀 miR-125b를 포함하는 간암 전이 진단 또는 예측용 바이오마커 및 이의 용도 |
| KR102131519B1 (ko) * | 2018-10-30 | 2020-07-07 | 가톨릭대학교 산학협력단 | 간암 전이 진단 또는 예후 예측용 바이오마커 및 이의 용도 |
| AU2020214843A1 (en) | 2019-01-31 | 2021-08-19 | Modernatx, Inc. | Methods of preparing lipid nanoparticles |
| CN113966397A (zh) | 2019-03-08 | 2022-01-21 | 黑曜石疗法公司 | 人碳酸酐酶2组合物和用于可调调节的方法 |
| US20220251577A1 (en) | 2019-06-24 | 2022-08-11 | Modernatx, Inc. | Endonuclease-resistant messenger rna and uses thereof |
| WO2020263985A1 (en) | 2019-06-24 | 2020-12-30 | Modernatx, Inc. | Messenger rna comprising functional rna elements and uses thereof |
| WO2021046451A1 (en) | 2019-09-06 | 2021-03-11 | Obsidian Therapeutics, Inc. | Compositions and methods for dhfr tunable protein regulation |
| BR112022014970A2 (pt) | 2020-01-31 | 2022-09-20 | Modernatx Inc | Métodos para preparar nanopartículas lipídicas |
| JP2023535225A (ja) | 2020-07-24 | 2023-08-16 | ストランド セラピューティクス インコーポレイテッド | 改変ヌクレオチドを含む脂質ナノ粒子 |
| IL300404A (en) | 2020-08-06 | 2023-04-01 | Modernatx Inc | Methods for preparing fat nanoparticles |
| CN112599202B (zh) * | 2020-12-24 | 2024-04-26 | 南华大学 | 疾病相关miRNA预测系统 |
| JP2024503000A (ja) | 2021-01-08 | 2024-01-24 | ストランド セラピューティクス インコーポレイテッド | 発現構築物およびその使用 |
| EP4334446A1 (en) | 2021-05-03 | 2024-03-13 | CureVac SE | Improved nucleic acid sequence for cell type specific expression |
| CA3245130A1 (en) | 2022-03-01 | 2023-09-07 | Crispr Therapeutics Ag | METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISORDERS RELATED TO ANGIOPOIETIN-TYPE PROTEIN 3 (ANGPTL3) |
| KR20250004731A (ko) | 2022-04-26 | 2025-01-08 | 스트랜드 세러퓨틱스 인코포레이티드 | 베네수엘라 말 뇌염 (vee) 레플리콘을 포함하는 지질 나노입자 및 이의 용도 |
| WO2024026475A1 (en) | 2022-07-29 | 2024-02-01 | Modernatx, Inc. | Compositions for delivery to hematopoietic stem and progenitor cells (hspcs) and related uses |
| US20250375391A1 (en) | 2022-07-29 | 2025-12-11 | Modernatx, Inc. | Lipid nanoparticle compositions comprising surface lipid derivatives and relates uses |
| EP4561547A1 (en) | 2022-07-29 | 2025-06-04 | ModernaTX, Inc. | Lipid nanoparticle compositions comprising phospholipid derivatives and related uses |
| CN121079317A (zh) | 2023-04-28 | 2025-12-05 | 深圳深信生物科技有限公司 | 经修饰的递送载体及其应用 |
| WO2024259373A1 (en) | 2023-06-14 | 2024-12-19 | Modernatx, Inc. | Compounds and compositions for delivery of therapeutic agents |
| WO2025160381A1 (en) | 2024-01-26 | 2025-07-31 | Modernatx, Inc. | Methods of preparing lipid nanoparticles |
| WO2025166202A1 (en) | 2024-01-31 | 2025-08-07 | Modernatx, Inc. | Lipid nanoparticle compositions comprising sialic acid derivatives and the uses thereof |
Family Cites Families (151)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4196265A (en) | 1977-06-15 | 1980-04-01 | The Wistar Institute | Method of producing antibodies |
| US4172124A (en) | 1978-04-28 | 1979-10-23 | The Wistar Institute | Method of producing tumor antibodies |
| US4608337A (en) | 1980-11-07 | 1986-08-26 | The Wistar Institute | Human hybridomas and the production of human monoclonal antibodies by human hybridomas |
| US4701409A (en) | 1984-11-15 | 1987-10-20 | The Wistar Institute | Detection of B-cell neoplasms |
| US4693975A (en) | 1984-11-20 | 1987-09-15 | The Wistar Institute | Human hybridroma fusion partner for production of human monoclonal antibodies |
| US5015568A (en) | 1986-07-09 | 1991-05-14 | The Wistar Institute | Diagnostic methods for detecting lymphomas in humans |
| US5202429A (en) | 1986-07-09 | 1993-04-13 | The Wistar Institute | DNA molecules having human BCL-2 gene sequences |
| US5198338A (en) | 1989-05-31 | 1993-03-30 | Temple University | Molecular probing for human t-cell leukemia and lymphoma |
| US5149628A (en) | 1989-11-15 | 1992-09-22 | Temple University | Methods for detecting bcl-3 gene in human leukemias |
| US6040140A (en) | 1991-12-11 | 2000-03-21 | Thomas Jefferson University | Methods for screening and treating leukemias resulting from all-1 region chromosome abnormalities |
| WO1993012136A1 (en) | 1991-12-11 | 1993-06-24 | Thomas Jefferson University | Detection and treatment of acute leukemias resulting from chromosome abnormalities in the all-1 region |
| US5633135A (en) | 1991-12-11 | 1997-05-27 | Thomas Jefferson University | Chimeric nucleic acids and proteins resulting from ALL-1 region chromosome abnormalities |
| ES2191018T3 (es) | 1992-10-29 | 2003-09-01 | Univ Jefferson | Procedimiento para detectar micrometastasis de cancer de prostata. |
| US5674682A (en) | 1992-10-29 | 1997-10-07 | Thomas Jefferson University | Nucleic acid primers for detecting micrometastasis of prostate cancer |
| US7175995B1 (en) | 1994-10-27 | 2007-02-13 | Thomas Jefferson University | TCL-1 protein and related methods |
| US5985598A (en) | 1994-10-27 | 1999-11-16 | Thomas Jefferson University | TCL-1 gene and protein and related methods and compositions |
| US5695944A (en) | 1995-05-05 | 1997-12-09 | Thomas Jefferson University | Modulation of bcl-2 phosphorylation |
| US5567586A (en) | 1995-05-18 | 1996-10-22 | Thomas Jefferson University | Methods of indentifying solid tumors with chromosome abnormalities in the ALL-1 region |
| US5928884A (en) | 1996-02-09 | 1999-07-27 | Croce; Carlo M. | FHIT proteins and nucleic acids and methods based thereon |
| US6242212B1 (en) | 1996-02-09 | 2001-06-05 | Thomas Jefferson University | Fragile histidine triad (FHIT) nucleic acids and methods of producing FHIT proteins |
| US6187536B1 (en) | 1997-02-18 | 2001-02-13 | Thomas Jefferson University | Methods of identifying and detecting pancreatic cancer |
| EP0972083A1 (en) | 1997-04-04 | 2000-01-19 | THE TEXAS A&M UNIVERSITY SYSTEM | Noninvasive detection of colonic biomarkers using fecal messenger rna |
| WO2000003685A2 (en) | 1998-07-20 | 2000-01-27 | Thomas Jefferson University | Nitrilase homologs |
| WO2000005419A1 (en) | 1998-07-24 | 2000-02-03 | Yeda Research And Development Company Ltd. | Prevention of metastasis with 5-aza-2'-deoxycytidine |
| US7141417B1 (en) | 1999-02-25 | 2006-11-28 | Thomas Jefferson University | Compositions, kits, and methods relating to the human FEZ1 gene, a novel tumor suppressor gene |
| WO2000055169A1 (en) | 1999-03-15 | 2000-09-21 | Thomas Jefferson University | TCL-1b GENE AND PROTEIN AND RELATED METHODS AND COMPOSITIONS |
| US7163801B2 (en) | 1999-09-01 | 2007-01-16 | The Burnham Institute | Methods for determining the prognosis for cancer patients using tucan |
| US6891031B2 (en) | 2000-02-18 | 2005-05-10 | The Regents Of The University Of California | Coordinate cytokine regulatory sequences |
| US20010026796A1 (en) | 2000-03-14 | 2001-10-04 | Croce Carlo M. | TCL1 enhances Akt kinase activity and mediates its nuclear translocation |
| JP2004516002A (ja) | 2000-04-11 | 2004-06-03 | トーマス・ジェファーソン・ユニバーシティー | Ｆｈｉｔ欠損マウスにおけるミュア−トール様症候群 |
| WO2001087958A2 (en) | 2000-05-16 | 2001-11-22 | Thomas Jefferson University | CRYSTAL STRUCTURE OF WORM NitFhit REVEALS THAT A Nit TETRAMER BINDS TWO Fhit DIMERS |
| US7060811B2 (en) | 2000-10-13 | 2006-06-13 | Board Of Regents, The University Of Texas System | WWOX: a tumor suppressor gene mutated in multiple cancers |
| US20040033502A1 (en) | 2001-03-28 | 2004-02-19 | Amanda Williams | Gene expression profiles in esophageal tissue |
| US20050176025A1 (en) | 2001-05-18 | 2005-08-11 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA) |
| WO2003029459A2 (en) | 2001-09-28 | 2003-04-10 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Micro-rna molecules |
| US7371736B2 (en) | 2001-11-07 | 2008-05-13 | The Board Of Trustees Of The University Of Arkansas | Gene expression profiling based identification of DKK1 as a potential therapeutic targets for controlling bone loss |
| GB0128898D0 (en) | 2001-12-03 | 2002-01-23 | Biotech Res Ventures Pte Ltd | Materials and methods relating to the stabilization and activation of a tumour suppressor protein |
| CA2478065C (en) | 2002-03-08 | 2013-01-08 | Eisai Co. Ltd. | Macrocyclic compounds useful as pharmaceuticals |
| US20060084059A1 (en) | 2002-04-08 | 2006-04-20 | Tai-Tung Yip | Serum biomarkers in hepatocellular carcinoma |
| US20040078834A1 (en) | 2002-04-29 | 2004-04-22 | Croce Carlo M. | Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression |
| JP2005528115A (ja) | 2002-05-31 | 2005-09-22 | ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ | 幹細胞および癌幹細胞を同定および単離する方法 |
| US20050260639A1 (en) | 2002-09-30 | 2005-11-24 | Oncotherapy Science, Inc. | Method for diagnosing pancreatic cancer |
| US20050266443A1 (en) | 2002-10-11 | 2005-12-01 | Thomas Jefferson University | Novel tumor suppressor gene and compositions and methods for making and using the same |
| CA2501602A1 (en) | 2002-10-11 | 2004-04-22 | Thomas Jefferson University | Novel tumor suppressor gene and compositions and methods for making and using the same |
| CN102304570B (zh) | 2002-11-13 | 2015-01-21 | 托马斯杰斐逊大学 | 用于癌症诊断和治疗的组合物和方法 |
| US7250496B2 (en) | 2002-11-14 | 2007-07-31 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
| WO2004071464A2 (en) | 2003-02-12 | 2004-08-26 | Johns Hopkins University School Of Medicine | Diagnostic application of differentially-expressed genes in lympho-hematopoietic stem cells |
| WO2004079013A1 (en) | 2003-03-03 | 2004-09-16 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer |
| US7183384B2 (en) | 2003-03-06 | 2007-02-27 | A & G Pharmaceutical, Inc. | Monoclonal antibody 7H11 reactive with human cancer |
| WO2004098377A2 (en) | 2003-05-02 | 2004-11-18 | Thomas Jefferson University | Methods and compositions for diagnosis and therapy of parkin-associated disorders |
| US20050069918A1 (en) | 2003-05-29 | 2005-03-31 | Francois Claret | JAB1 as a prognostic marker and a therapeutic target for human cancer |
| BRPI0411526A (pt) | 2003-06-18 | 2006-08-01 | Genelux Corp | vìrus de vaccinia e outros microrganismos recombinates modificados e usos dos mesmos |
| US8106180B2 (en) | 2003-08-07 | 2012-01-31 | Whitehead Institute For Biomedical Research | Methods and products for expression of micro RNAs |
| US20050037362A1 (en) | 2003-08-11 | 2005-02-17 | Eppendorf Array Technologies, S.A. | Detection and quantification of siRNA on microarrays |
| US8412541B2 (en) | 2003-08-14 | 2013-04-02 | Edda Technology, Inc. | Method and system for intelligent qualitative and quantitative analysis for medical diagnosis |
| WO2005020795A2 (en) | 2003-08-25 | 2005-03-10 | The Johns Hopkins University | Method of diagnosis and treatment of pancreatic endocrine neoplasms based on differntial gene expression analysis |
| CA2539651A1 (en) | 2003-09-22 | 2005-04-07 | Rosetta Inpharmatics Llc | Synthetic lethal screen using rna interference |
| US20070054849A1 (en) | 2003-09-24 | 2007-03-08 | Oncotherapy Science, Inc. | Method for diagnosing hepatocellular carcinomas |
| US20050186589A1 (en) | 2003-11-07 | 2005-08-25 | University Of Massachusetts | Interspersed repetitive element RNAs as substrates, inhibitors and delivery vehicles for RNAi |
| US20050164252A1 (en) | 2003-12-04 | 2005-07-28 | Yeung Wah Hin A. | Methods using non-genic sequences for the detection, modification and treatment of any disease or improvement of functions of a cell |
| DE602004031881D1 (de) | 2003-12-19 | 2011-04-28 | Univ California | Verfahren und materialien zur beurteilung von prostatakrebstherapien |
| WO2005078096A2 (en) | 2004-02-09 | 2005-08-25 | University Of Massachusetts | Dual functional oligonucleotides for use in repressing mutant gene expression |
| CA2554818A1 (en) | 2004-02-09 | 2005-08-25 | Thomas Jefferson University | Diagnosis and treatment of cancers with microrna located in or near cancer-associated chromosomal features |
| US8142994B2 (en) | 2004-02-23 | 2012-03-27 | Erasmus University Medical Center Rotterdam | Classification, diagnosis and prognosis of acute myeloid leukemia by gene expression profiling |
| US20060134639A1 (en) * | 2004-04-06 | 2006-06-22 | Huffel Christophe V | Method for the determination of cellular transcriptional regulation |
| US7365058B2 (en) | 2004-04-13 | 2008-04-29 | The Rockefeller University | MicroRNA and methods for inhibiting same |
| US7811759B2 (en) * | 2004-04-20 | 2010-10-12 | Jian Han | Method for detecting ncRNA |
| CA2566519C (en) | 2004-05-14 | 2020-04-21 | Rosetta Genomics Ltd. | Micrornas and uses thereof |
| EP2290070B1 (en) | 2004-05-28 | 2015-03-25 | Asuragen, Inc. | Methods and compositions involving microRNA |
| US7635563B2 (en) | 2004-06-30 | 2009-12-22 | Massachusetts Institute Of Technology | High throughput methods relating to microRNA expression analysis |
| US20060037088A1 (en) | 2004-08-13 | 2006-02-16 | Shulin Li | Gene expression levels as predictors of chemoradiation response of cancer |
| JP2008511678A (ja) | 2004-09-02 | 2008-04-17 | イェール ユニバーシティ | マイクロｒｎａによるオンコジーンの調節 |
| US7592441B2 (en) | 2004-10-04 | 2009-09-22 | Rosetta Genomics Ltd | Liver cancer-related nucleic acids |
| US7642348B2 (en) | 2004-10-04 | 2010-01-05 | Rosetta Genomics Ltd | Prostate cancer-related nucleic acids |
| FR2877350B1 (fr) | 2004-11-03 | 2010-08-27 | Centre Nat Rech Scient | IDENTIFICATION ET UTILISATION DE miRNAs IMPLIQUES DANS LA DIFFERENCIATION DE CELLULES ISSUES D'UNE LEUCEMIE MYELOIDE |
| ES2534302T3 (es) | 2004-11-12 | 2015-04-21 | Asuragen, Inc. | Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN |
| WO2006066158A2 (en) | 2004-12-14 | 2006-06-22 | Alnylam Pharmaceuticals, Inc. | Rnai modulation of mll-af4 and uses thereof |
| US20060185027A1 (en) | 2004-12-23 | 2006-08-17 | David Bartel | Systems and methods for identifying miRNA targets and for altering miRNA and target expression |
| EP1838870A2 (en) | 2004-12-29 | 2007-10-03 | Exiqon A/S | NOVEL OLIGONUCLEOTIDE COMPOSITIONS AND PROBE SEQUENCES USEFUL FOR DETECTION AND ANALYSIS OF MICRORNAS AND THEIR TARGET MRNAs |
| US8071306B2 (en) | 2005-01-25 | 2011-12-06 | Merck Sharp & Dohme Corp. | Methods for quantitating small RNA molecules |
| WO2006081284A2 (en) | 2005-01-25 | 2006-08-03 | Rosetta Inpharmatics Llc | Methods for quantitating small rna molecules |
| US20070065840A1 (en) | 2005-03-23 | 2007-03-22 | Irena Naguibneva | Novel oligonucleotide compositions and probe sequences useful for detection and analysis of microRNAS and their target mRNAS |
| GB2425311A (en) | 2005-04-15 | 2006-10-25 | Ist Superiore Sanita | Micro RNA against kit protein |
| EP2631292A3 (en) | 2005-04-29 | 2013-11-20 | The Rockefeller University | Human microRNAs and methods for inhibiting same |
| US20090209621A1 (en) | 2005-06-03 | 2009-08-20 | The Johns Hopkins University | Compositions and methods for decreasing microrna expression for the treatment of neoplasia |
| US20070065844A1 (en) | 2005-06-08 | 2007-03-22 | Massachusetts Institute Of Technology | Solution-based methods for RNA expression profiling |
| US20060292616A1 (en) | 2005-06-23 | 2006-12-28 | U.S. Genomics, Inc. | Single molecule miRNA-based disease diagnostic methods |
| JP5489459B2 (ja) | 2005-08-01 | 2014-05-14 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション | 乳癌の診断、予後及び治療のためのマイクロｒｎａに基づいた方法及び組成物 |
| WO2007021896A2 (en) | 2005-08-10 | 2007-02-22 | Alnylam Pharmaceuticals, Inc. | Chemically modified oligonucleotides for use in modulating micro rna and uses thereof |
| US20070213292A1 (en) | 2005-08-10 | 2007-09-13 | The Rockefeller University | Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof |
| CN101296702B (zh) | 2005-09-12 | 2012-11-28 | 俄亥俄州立大学研究基金会 | 用于诊断或治疗bcl2相关癌症的组合物和方法 |
| CN101312740A (zh) | 2005-10-05 | 2008-11-26 | 俄亥俄州立大学研究基金会 | Wwox基因、包含该基因的载体和在癌症治疗中的用途 |
| US7390792B2 (en) | 2005-12-15 | 2008-06-24 | Board Of Regents, The University Of Texas System | MicroRNA1 therapies |
| ES2536423T3 (es) | 2006-01-05 | 2015-05-25 | The Ohio State University Research Foundation | Métodos basados en microARN para el diagnóstico de cáncer de próstata |
| ES2553442T3 (es) | 2006-01-05 | 2015-12-09 | The Ohio State University Research Foundation | Procedimientos basados en los microARN para el diagnóstico, pronóstico y tratamiento del cáncer de pulmón |
| WO2007081680A2 (en) | 2006-01-05 | 2007-07-19 | The Ohio State University Research Foundation | Microrna expression abnormalities in pancreatic endocrine and acinar tumors |
| WO2008051260A1 (en) | 2006-01-13 | 2008-05-02 | Battelle Memorial Institute | Methods for assessing copd-retlated diseases |
| EP2369012A1 (en) | 2006-03-20 | 2011-09-28 | The Ohio State University Research Foundation | Micro-RNA fingerprints during human megakaryocytopoiesis |
| WO2007112097A2 (en) | 2006-03-24 | 2007-10-04 | Children's Medical Center Corporation | Novel signature self renewal gene expression programs |
| WO2007127190A2 (en) | 2006-04-24 | 2007-11-08 | The Ohio State University Research Foundation | Pre-b cell proliferation and lymphoblastic leukemia/high-grade lymphoma in mir155 transgenic mice |
| ES2442890T3 (es) | 2006-07-13 | 2014-02-14 | The Ohio State University Research Foundation | Métodos y composiciones basados en micro-ARN para el diagnóstico y el tratamiento de enfermedades relacionadas con el colon |
| US20080193943A1 (en) | 2006-09-05 | 2008-08-14 | Abbott Laboratories | Companion diagnostic assays for cancer therapy |
| ES2374446T3 (es) | 2006-09-19 | 2012-02-16 | The Ohio State University Research Foundation | Expresión de tcl1 en la leucemia linfocítica crónica (llc) regulada por mir-29 y mir-181. |
| CA2663962A1 (en) | 2006-09-19 | 2008-03-27 | Asuragen, Inc. | Mir-15, mir-26, mir-31,mir-145, mir-147, mir-188, mir-215, mir-216, mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention |
| WO2008036741A2 (en) | 2006-09-19 | 2008-03-27 | Asuragen, Inc. | Mir-200 regulated genes and pathways as targets for therapeutic intervention |
| EP2115138A2 (en) | 2006-09-19 | 2009-11-11 | Asuragen, Inc. | Micrornas differentially expressed in pancreatic diseases and uses thereof |
| EP2087135B8 (en) | 2006-11-01 | 2013-07-24 | The Ohio State University Research Foundation | Microrna expression signature for predicting survival and metastases in hepatocellular carcinoma |
| US8293684B2 (en) | 2006-11-29 | 2012-10-23 | Exiqon | Locked nucleic acid reagents for labelling nucleic acids |
| WO2008070082A2 (en) | 2006-12-04 | 2008-06-12 | The Johns Hopkins University | Stem-progenitor cell specific micro-ribonucleic acids and uses thereof |
| WO2008073915A2 (en) | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | Micrornas differentially expressed in leukemia and uses thereof |
| AU2007333109A1 (en) | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | Functions and targets of let-7 micro RNAs |
| AU2007333107A1 (en) | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | miR-21 regulated genes and pathways as targets for therapeutic intervention |
| CA2671194A1 (en) | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | Mir-20 regulated genes and pathways as targets for therapeutic intervention |
| CA2671270A1 (en) | 2006-12-29 | 2008-07-17 | Asuragen, Inc. | Mir-16 regulated genes and pathways as targets for therapeutic intervention |
| CN105256004A (zh) | 2007-01-31 | 2016-01-20 | 俄亥俄州立大学研究基金会 | 用于急性髓细胞白血病(aml)的诊断、预后和治疗的基于微rna的方法和组合物 |
| AU2008237036A1 (en) | 2007-04-10 | 2008-10-16 | Dcb-Usa Llc | Predicting post-treatment survival in cancer patients with microRNAs |
| EP2142659A4 (en) | 2007-04-30 | 2010-06-09 | Univ Ohio State Res Found | METHOD FOR THE DISTINCTION OF PANCREATIC CANCER OF NORMAL IMMERSION SPECTRUM FUNCTIONS AND CHRONIC IMMERSION IMAGING IGNITION |
| US20090005336A1 (en) | 2007-05-08 | 2009-01-01 | Zhiguo Wang | Use of the microRNA miR-1 for the treatment, prevention, and diagnosis of cardiac conditions |
| US20090131354A1 (en) | 2007-05-22 | 2009-05-21 | Bader Andreas G | miR-126 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION |
| US20090232893A1 (en) | 2007-05-22 | 2009-09-17 | Bader Andreas G | miR-143 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION |
| WO2008154098A2 (en) | 2007-06-07 | 2008-12-18 | Wisconsin Alumni Research Foundation | Reagents and methods for mirna expression analysis and identification of cancer biomarkers |
| WO2008154333A2 (en) | 2007-06-08 | 2008-12-18 | Asuragen, Inc. | Mir-34 regulated genes and pathways as targets for therapeutic intervention |
| ES2537349T3 (es) | 2007-06-08 | 2015-06-05 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Métodos para determinar un subtipo de carcinoma hepatocelular |
| CN101918424A (zh) | 2007-06-15 | 2010-12-15 | 俄亥俄州立大学研究基金会 | 用于靶向由Drosha介导的微小RNA加工的致癌ALL-1融合蛋白 |
| JP2010535782A (ja) | 2007-07-31 | 2010-11-25 | ズィ、オハイオウ、ステイト、ユーニヴァーサティ、リサーチ、ファウンデイシャン | Ｄｎｍｔ３ａ及びｄｎｍｔ３ｂを標的にすることによるメチル化を元に戻す方法 |
| ES2562077T3 (es) | 2007-08-03 | 2016-03-02 | The Ohio State University Research Foundation | Regiones ultraconservadas que codifican ARNnc |
| EP2183593B1 (en) | 2007-08-22 | 2016-01-13 | The Ohio State University Research Foundation | Methods and compositions for inducing deregulation of epha7 and erk phosphorylation in human acute leukemias |
| US20090061424A1 (en) | 2007-08-30 | 2009-03-05 | Sigma-Aldrich Company | Universal ligation array for analyzing gene expression or genomic variations |
| WO2009033140A1 (en) | 2007-09-06 | 2009-03-12 | The Ohio State University Research Foundation | Microrna signatures in human ovarian cancer |
| AU2008310704B2 (en) | 2007-10-11 | 2014-03-20 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Methods and compositions for the diagnosis and treatment of esphageal adenocarcinomas |
| EP2201112A4 (en) | 2007-10-26 | 2011-02-02 | Univ Ohio State Res Found | METHOD FOR IDENTIFYING FHIT INTERACTION AND USE |
| US8575121B2 (en) | 2007-11-12 | 2013-11-05 | The United States of America as represented by the Secetary of the Department of Health and Human Services | Therapeutic applications of p53 isoforms in regenerative medicine, aging and cancer |
| US20090123933A1 (en) | 2007-11-12 | 2009-05-14 | Wake Forest University Health Sciences | Microrna biomarkers in lupus |
| WO2009070653A1 (en) | 2007-11-30 | 2009-06-04 | The Ohio State University Research Foundation | Microrna expression profiling and targeting in peripheral blood in lung cancer |
| WO2009070805A2 (en) | 2007-12-01 | 2009-06-04 | Asuragen, Inc. | Mir-124 regulated genes and pathways as targets for therapeutic intervention |
| US20090192114A1 (en) | 2007-12-21 | 2009-07-30 | Dmitriy Ovcharenko | miR-10 Regulated Genes and Pathways as Targets for Therapeutic Intervention |
| DK2245199T3 (da) | 2008-02-01 | 2014-02-03 | Gen Hospital Corp | Anvendelse af mikrovesikler i diagnosticering, prognosticering og behandling af medicinske sygdomme og tilstande |
| EP2260110B1 (en) | 2008-02-08 | 2014-11-12 | Asuragen, INC. | miRNAs DIFFERENTIALLY EXPRESSED IN LYMPH NODES FROM CANCER PATIENTS |
| US20110034538A1 (en) | 2008-02-28 | 2011-02-10 | The Ohio State University Research Foundation | MicroRNA-Based Methods and Compositions for the Diagnosis, Prognosis and Treatment of Gastric Cancer |
| CA2717030A1 (en) | 2008-02-28 | 2009-09-03 | The Ohio State University Research Foundation | Microrna signatures associated with cytogenetics and prognosis in acute myeloid leukemia (aml) and uses thereof |
| ES2600165T3 (es) | 2008-02-28 | 2017-02-07 | The Ohio State University Research Foundation | Antagonistas de miR-32 para aumentar la respuesta del cáncer de próstata a la apoptosis |
| JP2011517932A (ja) | 2008-02-28 | 2011-06-23 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション | ヒト慢性リンパ球性白血病（ｃｃｌ）と関連するマイクロｒｎａシグネチャーおよびその使用 |
| WO2009111643A2 (en) | 2008-03-06 | 2009-09-11 | Asuragen, Inc. | Microrna markers for recurrence of colorectal cancer |
| US20090253780A1 (en) | 2008-03-26 | 2009-10-08 | Fumitaka Takeshita | COMPOSITIONS AND METHODS RELATED TO miR-16 AND THERAPY OF PROSTATE CANCER |
| EP2990487A1 (en) | 2008-05-08 | 2016-03-02 | Asuragen, INC. | Compositions and methods related to mirna modulation of neovascularization or angiogenesis |
| CN102112110A (zh) | 2008-06-06 | 2011-06-29 | 米尔纳医疗股份有限公司 | 用于RNAi试剂体内递送的新型组合物 |
| US9125923B2 (en) | 2008-06-11 | 2015-09-08 | The Ohio State University | Use of MiR-26 family as a predictive marker for hepatocellular carcinoma and responsiveness to therapy |
| WO2010019694A1 (en) | 2008-08-12 | 2010-02-18 | The Ohio State University Research Foundation | Micro-rna-based compositions and methods for the diagnosis, prognosis and treatment of multiple myeloma |
| US20110311555A1 (en) | 2008-11-21 | 2011-12-22 | The Ohio State University | Tc11 as a Transcriptional Regulator |
| US20110275534A1 (en) | 2008-12-05 | 2011-11-10 | The Ohio State University | MicroRNA-Based Methods and Compositions for the Diagnosis, Prognosis and Treatment of Ovarian Cancer Using a Real-Time PCR Platform |
| CN102549166A (zh) | 2009-02-26 | 2012-07-04 | 俄亥俄州立大学研究基金会 | 从未吸烟者中的MicroRNA及相关材料和方法 |
-
2007
- 2007-11-01 EP EP07867402.5A patent/EP2087135B8/en not_active Not-in-force
- 2007-11-01 CA CA002667617A patent/CA2667617A1/en not_active Abandoned
- 2007-11-01 WO PCT/US2007/023660 patent/WO2008054828A2/en not_active Ceased
- 2007-11-01 JP JP2009535366A patent/JP5501766B2/ja not_active Expired - Fee Related
- 2007-11-01 ES ES07867402T patent/ES2425416T3/es active Active
- 2007-11-01 US US12/513,219 patent/US8252538B2/en not_active Expired - Fee Related
- 2007-11-01 AU AU2007314212A patent/AU2007314212B2/en not_active Ceased
-
2012
- 2012-08-27 US US13/595,192 patent/US20120329672A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008054828A9 (en) | 2008-06-19 |
| US20100120898A1 (en) | 2010-05-13 |
| US8252538B2 (en) | 2012-08-28 |
| EP2087135B1 (en) | 2013-06-19 |
| ES2425416T3 (es) | 2013-10-15 |
| AU2007314212A1 (en) | 2008-05-08 |
| CA2667617A1 (en) | 2008-05-08 |
| EP2087135A2 (en) | 2009-08-12 |
| WO2008054828A3 (en) | 2008-12-11 |
| US20120329672A1 (en) | 2012-12-27 |
| EP2087135A4 (en) | 2009-12-23 |
| AU2007314212B2 (en) | 2014-05-29 |
| WO2008054828A2 (en) | 2008-05-08 |
| JP2010508042A (ja) | 2010-03-18 |
| EP2087135B8 (en) | 2013-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5501766B2 (ja) | 肝細胞癌における生存および転移を予測するためのマイクロｒｎａ発現サイン | |
| Spahn et al. | Expression of microRNA‐221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence | |
| Budhu et al. | Identification of metastasis‐related microRNAs in hepatocellular carcinoma | |
| Borrelli et al. | miRNA expression profiling of ‘noninvasive follicular thyroid neoplasms with papillary-like nuclear features' compared with adenomas and infiltrative follicular variants of papillary thyroid carcinomas | |
| Schaefer et al. | Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma | |
| Huang et al. | Bead‐based microarray analysis of microRNA expression in hepatocellular carcinoma: miR‐338 is downregulated | |
| Wach et al. | MicroRNA profiles of prostate carcinoma detected by multiplatform microRNA screening | |
| Calin et al. | MicroRNA signatures in human cancers | |
| AU2008248319B2 (en) | Methods for differentiating pancreatic cancer from normal pancreatic function and/or chronic pancreatitis | |
| Jamieson et al. | MicroRNA molecular profiles associated with diagnosis, clinicopathologic criteria, and overall survival in patients with resectable pancreatic ductal adenocarcinoma | |
| Ramdas et al. | miRNA expression profiles in head and neck squamous cell carcinoma and adjacent normal tissue | |
| Schaefer et al. | Diagnostic, prognostic and therapeutic implications of microRNAs in urologic tumors | |
| Qu et al. | Circulating miRNAs: promising biomarkers of human cancer | |
| CN108220433B (zh) | 乳腺癌标志物及其应用 | |
| Nakka et al. | Biomarker significance of plasma and tumor miR-21, miR-221, and miR-106a in osteosarcoma | |
| Sandhu et al. | Potential applications of microRNAs in cancer diagnosis, prognosis, and treatment | |
| Ludvíková et al. | Pathobiology of microRNAs and their emerging role in thyroid fine-needle aspiration | |
| Huang et al. | MicroRNA expression profile in non‐cancerous colonic tissue associated with lymph node metastasis of colon cancer | |
| Verma et al. | MicroRNAs in non-small cell lung cancer invasion and metastasis: from the perspective of the radiation oncologist | |
| US10059998B2 (en) | Microrna signature as an indicator of the risk of early recurrence in patients with breast cancer | |
| KR20110015013A (ko) | 결장직장암의 평가 방법 및 여기에 사용하기 위한 조성물 | |
| Bleckmann et al. | Integrated miRNA and mRNA profiling of tumor-educated macrophages identifies prognostic subgroups in estrogen receptor-positive breast cancer | |
| Peter et al. | A selective screening platform reveals unique global expression patterns of microRNAs in a cohort of human soft-tissue sarcomas | |
| AU2013267038B2 (en) | Methods for differentiating pancreatic cancer from normal pancreatic function and/or chronic pancreatitis | |
| Sandhu | A systems biology approach to integrated molecular analysis in pancreatic and periampullary adenocarcinoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20101019 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111012 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120116 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121221 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130318 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20131001 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140120 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20140128 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140217 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140312 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5501766 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |